[Targeted therapy in the treatment of solid tumors and in hematology-oncology. Advances and disappointments].
The development and clinical introduction of targeted therapies has resulted in significant progress for the treatment of malignant diseases. These forms of therapy supplement traditional methods of chemotherapy, radiation, and surgery. As new therapies increase the complexity of therapeutic options in oncology, the treatment costs steadily climb as well. Parameters need to be identified which will predict a response to new substances, and this effort is the subject of ongoing studies.
Jochims
C
C
Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany.
Mazitschek
U
U
Jäger
D
D
Goldschmidt
H
H
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000639:trends; D016503:Drug Delivery Systems / Q000639:trends*; D018390:Gene Targeting / Q000639:trends*; D015316:Genetic Therapy / Q000639:trends*; D019337:Hematologic Neoplasms / Q000235:genetics / Q000628:therapy*; D006405:Hematology / Q000639:trends; D006801:Humans; D008495:Medical Oncology / Q000639:trends; D016896:Treatment Outcome
D000970:Antineoplastic Agents